Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Vikas Gupta, Yizhe Chen, Patrick Brown, Danny Jeyaraju, Moshe Talpaz, Ruben Mesa, Richard Pilot, Christopher Hernandez, Jia Wang, Jean-Jacques Kiladjian, Alessandro Vannucchi, Claire Harrison

Blood (2024) 144 (Supplement 1): 6623.

https://doi.org/10.1182/blood-2024-194223

Published: 2024

Journal Articles

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Danny Jeyaraju, Sheida Hayati, Jia Wang, Claire N Harrison, Jean-Jacques Kiladjian, Christopher Hernandez, Patrick Brown, Daniel Lopes De Menezes, Anita K. Gandhi, Rajasekhar N.V.S. Suragani

Blood (2023) 142 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2023-180419

Published: 2023

Journal Articles

Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway

Danny Jeyaraju, Ann Polonskaia, Chih-Chao Hsu, Patrick R Hagner, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2023-181898

Published: 2023

Journal Articles

Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis- (MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study

Danny Jeyaraju, Sheida Hayati, Niloufar Marsousi, Aaron T. Gerds, Francesco Passamonti, Fabian Sanabria, Sadanand Vodala, Anita K. Gandhi, Rajasekhar N.V.S. Suragani

Blood (2023) 142 (Supplement 1): 6330.

https://doi.org/10.1182/blood-2023-182155

Published: 2023

Journal Articles

Modeling Tumor Microenvironment Interactions of Imid Sensitive and Resistant Cells in 3D Organotypic Culture Models

Aarif Ahsan, PhD, Danny Jeyaraju, Kamlesh Bisht, Patrick R. Hagner, PhD, Chad C. Bjorklund, William E Pierceall, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 5622.

https://doi.org/10.1182/blood-2018-99-118885

Published: 2018

NARROW

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway

Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis- (MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study

Modeling Tumor Microenvironment Interactions of Imid Sensitive and Resistant Cells in 3D Organotypic Culture Models

Email alerts

ASH Publications

American Society of Hematology

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway

Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis- (MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study

Modeling Tumor Microenvironment Interactions of Imid Sensitive and Resistant Cells in 3D Organotypic Culture Models

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only